ASCO® 2025 Highlights: Presenter Vignette – Dickon Hayne
Dickon Hayne
MD, FRCS, MBBS
UWA Medical School
LBA4504
Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301).
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
